New Uses for Old Drugs in HIV Infection: The Role of Hydroxyurea, Cyclosporin and Thalidomide

Ravot, E.; Lisziewicz, J.; Lori, F.
December 1999
Drugs;Dec1999, Vol. 58 Issue 6, p953
Academic Journal
The tenacious effort to develop new, specific agents to treat HIV infection is currently accompanied by a reconsideration of existing drugs on the basis of their known or putative effects on the retroviral life cycle and/or the tuning of immune mechanisms. Three specific ‘older’ compounds that interfere with HIV infection by both a direct antiviral activity, and a modulation of T-cell activation and proliferation have received the most attention. Hydroxurea, a classical chemotherapeutic agent, inhibits retroviral reverse transcription by targeting a cellular enzyme responsible for the synthesis of deoxynucleoside triphosphates. It may also have a role in reducing viral load while maintaining low numbers of potential target T cells. Beneficial effects of hydroxyurea in combination with didanosine and/or stavudine on viral load have been shown in a number of clinical trials. Cyclosporin, a known immunosuppresant, blocks the activation of T cells, hence reducing the permissivity to HIV, and also prevents proper HIV virion maturation. However, clinical studies have produced conflicting results in HIV-infected patients with regard to immunological and disease effects and toxicity. Thalidomide may have antiretroviral effects as a result of its primarily inhibitory effects on the production of tumour necrosis factor α (TNFα). TNFα induces expression of HIV from chronically infected cell lines by stimulating a cellular transcription factor, and blocking of TNFα-stimulated HIV replication by thalidomide has been shown in vitro and ex vivo. However, the effects on TNFα production in vivo have been inconsistent. Thalidomide has shown potential in treating some AIDS-related conditions [cachexia (weight loss and muscle wasting), and aphtous oral, oesophageal or genital ulcers]. However, because of its numerous and major adverse effects, thalidomide should always be used cautiously. In summary, some older drugs have potential as anti-HIV agents and offer the advantage of extensive clinical experience in other therapeutic areas. They should be considered as potential partners for the products emerging from more recent research and development.


Related Articles

  • Are we dermatologists or physicians (or both?). Levine, Norman // Dermatology Times;Dec2005, Vol. 26 Issue 12, p4 

    The article focuses on issues related to dermatology. In recent years, researchers have developed many new drugs, which are highly effective for treating cutaneous and internal diseases simultaneously. One such drug, cyclosporine, is used for treating a many T cell-mediated diseases, such as...

  • Thalidomide studied for HIV patients with aphthous ulcers.  // Dermatology Times;Jul97, Vol. 18 Issue 7, p3 

    Shows that thalidomide (Synovir) is an effective treatment for aphthous ulcereration of the mouth and oropharynx in HIV-infected patients. Patients and materials used in the study; Adverse effects with the thalidomide.

  • Thalidomide trial for diarrhea.  // AIDS Patient Care & STDs;Aug96, Vol. 10 Issue 4, p263 

    Reports on the trial conducted by Celgene Corp. to determine thalidomide's effectiveness in treating HIV-related diarrhea. Significant reduction of the number of bowel movements in an open trial in England.

  • Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected... Fu, Casey S.; Conteas, Chris N. // AIDS Patient Care & STDs;Dec98, Vol. 12 Issue 12, p903 

    Discusses the effectiveness of using thalidomide in the treatment of HIV-associated idiopathic colitis and proctitis. Cases of HIV-associated idiopathic colitis and proctitis; Long-term benefit of thalidomide; Speculations of the mechanism of action of thalidomide.

  • TRIAL WILL EVALUATE CYCLOSPORINE.  // AIDS Patient Care & STDs;Mar1999, Vol. 13 Issue 3, p202 

    Announces the recruitment of HIV patients with CD4 cell counts above 500 for a phase II placebo-controlled study of low-dose cyclosporine. Anecdotal reports of the potential of the immunosuppressant as an HIV treatment; Duration of the trial.

  • Safety, Tolerability, and Pharmacokinetic Effects of Thalidomide in Patients Infected with Human Immunodeficiency Virus: AIDS Clinical Trials Group 267. Wohl, David A.; Aweeka, Francesca T.; Schmitz, John; Pomerantz, Roger; Weng Cherng, Deborah; Spritzler, John; Fox, Lawrence; Simpson, David; Bell, Dawn; Holohan, M.K.; Thomas, Steven; Robinson, Wayne; Kaplan, Gilla; Teppler, Hedy // Journal of Infectious Diseases;5/1/2002, Vol. 185 Issue 9, p1359 

    Thalidomide is used to treat human immunodeficiency virus (HIV)-associated conditions, including aphthous ulcers and wasting syndrome. The safety, tolerability, and pharmacokinetics of a formulation of thalidomide with improved bioavailability in HIV-infected persons was examined in a...

  • Beginning to Make Progress against HIV. Wilfert, Catherine M. // New England Journal of Medicine;11/28/96, Vol. 335 Issue 22, p1678 

    Opinion. Discusses efforts to reduce perinatal human immunodeficiency virus (HIV) infection. Evidence of the preventive efficacy of zidovudine demonstrated by Sperling et al.; How Sperling's work, called Protocol 076, is being implemented in the United States; Details of three studies...

  • Primary Lamivudine Resistance in Acute/Early Human Immunodeficiency Virus Infection. Conway, Brian; Montessori, Valentina; Rouleau, Danielle; Montaner, Julio S.G.; O'Shaughnessy, Michael V.; Fransen, Signe; Shillington, Andrew; Weislow, Owen; Mayers, Douglas L. // Clinical Infectious Diseases;4/1/1999, Vol. 28 Issue 4, p910 

    Focuses on a study which described primary resistance to zidovudine in acute and early HIV infection. Patients and methods; Detection of drug resistance; Cases of transmission of resistant virus strains.

  • Early zidovudine treatment for patients with HIV infection.  // American Family Physician;12/1/1995, Vol. 52 Issue 8, p2358 

    Reports on a study on the use of early zidovudine treatment in asymptomatic patients with HIV infections in the United States, as presented in the August 17, 1995 issue of `New England Journal of Medicine.' Comparison between immediate and deferred zidovudine treatment; Effectiveness of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics